Agile Therapeutics (AGRX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AGRX shares.
View AGRX analyst ratings or view top-rated stocks.

Agile Therapeutics' stock was trading at $0.2270 on January 1st, 2023. Since then, AGRX stock has increased by 1,543.2% and is now trading at $3.73.
View the best growth stocks for 2023 here.

Agile Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 67,900 shares, an increase of 46.0% from the April 30th total of 46,500 shares. Based on an average trading volume of 25,800 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.9% of the shares of the company are short sold.
View Agile Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AGRX earnings forecast.

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings results on Wednesday, March, 22nd. The specialty pharmaceutical company reported ($9.00) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $1.50. The specialty pharmaceutical company had revenue of $4 million for the quarter, compared to analysts' expectations of $3.17 million. Agile Therapeutics had a negative trailing twelve-month return on equity of 2,658.43% and a negative net margin of 318.50%.

Agile Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Agile Therapeutics issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $25.00 million-$30.00 million, compared to the consensus revenue estimate of $21.66 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Agile Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Virtu Financial LLC (12.78%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGRX stock can currently be purchased for approximately $3.73.

Agile Therapeutics (NASDAQ:AGRX) has a market capitalization of $3.69 million and generates $10.88 million in revenue each year. The specialty pharmaceutical company earns $-25,410,000.00 in net income (profit) each year or ($172.91) on an earnings per share basis.

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The official website for the company is www.agiletherapeutics.com. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at info@agiletherapeutics.com.